https://www.thebodypro.com/category/pregnancy-childbirth-hiv/tag/croi-conference-on-retroviruses-and-opportunistic-infections
Pregnancy, Childbirth, and HIV

CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows Img

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

Research Is Still Exploring Best Treatment Strategies for Pregnant and Breastfeeding Women, Interactions With Contraceptives Img

Research Is Still Exploring Best Treatment Strategies for Pregnant and Breastfeeding Women, Interactions With Contraceptives

Several new studies presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI) underscore the complex ways that HIV risk and treatment adherence manifest among women of childbearing age.

CROI sign and podium

New Study Shows Women's HIV Risk Triples During Pregnancy, Quadruples Postpartum

Study highlights the need for PrEP and other HIV prevention strategies for pregnant women and new mothers in high-prevalence settings.

VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding Img

VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding

Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.

PREP in Pregnancy Does Not Increase Poor Birth Outcomes Img

PREP in Pregnancy Does Not Increase Poor Birth Outcomes

No increase in poor birth outcomes with PrEP used throughout pregnancy in the Partners Demonstration project.

Adverse Pregnancy Outcomes and Risk Factors in the PROMISE Trial Img

Adverse Pregnancy Outcomes and Risk Factors in the PROMISE Trial

While antiretroviral therapy in pregnancy reduced vertical transmission, it also increased the frequency of several adverse birth outcomes compared with antenatal zidovudine (AZT) alone.

Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study Img

Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study

HIV-positive pregnant women receiving lopinavir/ritonavir-based regimens were at higher risk of preterm delivery compared with those on NNRTI-based regimens.

No Increase in Adverse Birth Outcomes With Maternal TDF/FTC in U.S. Study Img

No Increase in Adverse Birth Outcomes With Maternal TDF/FTC in U.S. Study

Among pregnant women with HIV in the PROMISE trial, use of TDF/FTC/LPV/r was not associated with increased risk of adverse infant birth outcomes when compared to AZT/3TC/LPV/r or TDF/FTC/ATV/r.

Efavirenz, Tenofovir and Emtricitabine Associated With Fewest Adverse Birth Outcomes in Botswana Img

Efavirenz, Tenofovir and Emtricitabine Associated With Fewest Adverse Birth Outcomes in Botswana

Researchers compared birth outcomes with in-utero exposure from conception to the five most common antiretroviral therapy regimens used in Botswana.

Pharmacokinetics of Antiretrovirals in Pregnancy: Rilpivirine, Etravirine and Raltegravir Img

Pharmacokinetics of Antiretrovirals in Pregnancy: Rilpivirine, Etravirine and Raltegravir

Three posters at CROI 2015 described pharmacokinetics of antiretrovirals in pregnancy for rilpivirine, etravirine and raltegravir. None of the studies suggested that dose adjustment is required.